Capital Advisors Ltd. LLC Reduces Stake in Edwards Lifesciences Co. (NYSE:EW)

Capital Advisors Ltd. LLC decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 14.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,445 shares of the medical research company’s stock after selling 398 shares during the period. Capital Advisors Ltd. LLC’s holdings in Edwards Lifesciences were worth $181,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Y Intercept Hong Kong Ltd lifted its holdings in Edwards Lifesciences by 176.5% during the 4th quarter. Y Intercept Hong Kong Ltd now owns 38,221 shares of the medical research company’s stock worth $2,830,000 after purchasing an additional 24,398 shares in the last quarter. Union Bancaire Privee UBP SA bought a new position in Edwards Lifesciences in the 4th quarter worth about $1,120,000. Ascent Wealth Partners LLC bought a new position in Edwards Lifesciences in the 4th quarter worth about $263,000. Howard Capital Management Inc. increased its stake in Edwards Lifesciences by 5.5% in the 4th quarter. Howard Capital Management Inc. now owns 4,005 shares of the medical research company’s stock worth $296,000 after acquiring an additional 207 shares during the last quarter. Finally, Townsend & Associates Inc increased its stake in Edwards Lifesciences by 3.3% in the 4th quarter. Townsend & Associates Inc now owns 180,751 shares of the medical research company’s stock worth $12,647,000 after acquiring an additional 5,773 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. The Goldman Sachs Group upped their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Stifel Nicolaus upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Truist Financial restated a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Morgan Stanley upped their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Finally, Evercore ISI decreased their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a research note on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Trading Down 0.8 %

Shares of EW stock opened at $72.72 on Tuesday. The stock has a market capitalization of $42.89 billion, a PE ratio of 10.43, a P/E/G ratio of 4.82 and a beta of 1.11. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The business has a 50-day moving average of $72.83 and a 200 day moving average of $70.13. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares in the company, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the sale, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 26,489 shares of company stock worth $2,002,829. 1.29% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.